Phase 3 Clinical Program Announced for Monotherapy Treatment for MDD
The drug has shown statistically significant, clinically meaningful reductions in symptoms of depression, anhedonia.
Experimental Drug Slows Progression of Alzheimer Disease in Patients With Mild Impairment by 60%
Trial results underscore the importance of early diagnosis and treatment in patients with Alzheimer disease.
FDA Grants Traditional Approval to Leqembi for the Treatment of Alzheimer Disease
Announcement follows the FDA’s accelerated approval and unanimous endorsement of the drug earlier this year.
Study Explores Core Elements of Accelerated TMS for the Treatment of MDD
Researchers focused on elements across several categories, including brain state, cumulative exposure, and treatment and individualized parameters.
Study Explores Discrepancies Between Caregiver, Clinician Reports of Sleep Problems in Children
Although more than 90% of children had at least 1 caregiver-reported sleep problem, only 20% had a clinician-documented sleep problem.
US Surgeon General Issues Advisory on Impact of Social Media on Youth Mental Health
The advisory identifies positive and negative effects of social media usage and next steps for making social media safer for youth.
Researchers Explore Effects of rTMS on Patients With Geriatric Depression
Study investigates connections between rTMS and factors including depression and cognitive performance.
FDA Approves Long-acting Treatment for Schizophrenia in Adults
The risperidone formulation is the first FDA-approved treatment for this patient population to use technology enabling controlled release over time.
FDA Grants Final Approval for Treatment of Cataplexy in Adults With Narcolepsy
Treatment is now the first and only once-at-bedtime oxybate to be approved by the FDA for individuals with narcolepsy.
Progress Made Toward the Approval of Treatment of Agitation Associated With Alzheimer Dementia
If approved, the drug will be the first FDA-approved treatment for agitation associated with Alzheimer dementia in the United States.
Changing the Narrative: Mental Illness and Gun Violence
Public responses to mass shootings, in particular, often include speculations about the shooter’s mental state. But what is the real connection between gun violence and mental illness?
FDA Approves First Naloxone Product for Over-the-Counter Use
The AMA, substance abuse experts share their thoughts on this decision and what it means for psychiatric clinicians and their patients.
Music Therapy Helps Ease Depression in Children, Adolescents With ADHD
Study results show that the therapy activates serotonin (5-HT) and improves stress-coping ability.
Positive Top-Line Results Reported for Fed/Fast Study of Novel ADHD Treatment
Results show that the novel formulation of dexmethylphenidate can be taken either with or without food.
Governors Join Forces to Support Youth Mental Health
Leaders from across the United States aim to work together to develop bipartisan solutions for the youth mental health crisis.
FDA Announces Need for New Regulatory Pathway for CBD
The agency’s conclusions are based on regulatory oversight needed to manage risks associated with CBD and other cannabis-derived products.
Promising 6-Month Interim Results Reported for Treatment-Resistant Schizophrenia
The ongoing study demonstrated statistically significant improvements over baseline in comparison to results at 6 weeks.
Dementia in the News
What's the latest in dementia?
Positive Phase III Study Results Reported for Bipolar I Disorder Treatment in Adults
The novel atypical antipsychotic is already FDA-approved for the treatment of schizophrenia in adults.
Psychopharmacology Conference Offers New Research, Prescribing Tips
Check out the best clinical pearls from the 2022 Neuroscience Education Institute (NEI) Congress!
Study Debunks Association Between In Utero Antidepressant Exposure and ADHD Risk
The investigators suggested that future research explore the connection between ADHD risk in children and depression in pregnant parents.
Rolling NDA Submission of Zuranolone for MDD, PPD is Completed
This latest submission completes the FDA filing that was initiated in May.
Phase 1 Study of Apimostinel for Depression Doses First Participants
The drug is in development for the treatment of acute depressive disorders and depression with suicidality.
AMA Announces New Policies Supporting Reproductive Health Care Rights
Policies include opposition to government involvement in medical practice and support of access to abortion care.
Study Identifies Promising Potential Treatment for Alzheimer Disease
Results show comparisons between intranasal and intracerebroventricular distribution of an oxytocin derivative.
Motivating and Empowering Patients With Schizophrenia
Experts share the benefits of motivational interviewing when working with this patient population—and how clinicians can incorporate it into their practice.
Bipolar I vs Bipolar II: What are the Major Differences in Presentation and Treatment?
An expert discusses key differences and some ways to avoid missing the appropriate diagnosis in these patient populations.
Study Explores Impact of Circadian Pathway, Insomnia Risk Genes on Sleep Disturbance in Autism
Connections between autism risk, sleep disturbances, insomnia risk genes and circadian pathways were analyzed.
New Scholarship Announced for Underrepresented Racial and Ethnic Groups
The American Academy of Psychiatry and the Law scholarship aims to foster a welcoming and supportive environment for forensic psychiatrists of color.
Study Explores Effects of Experimenter Sex on Ketamine Response
The underlying neural mechanisms identified may help clinicians better understand ketamine response in human patients.
2 Clarke Drive Cranbury, NJ 08512